Swati T. Sharma

Swati T. Sharma

Patent Agent

Patents and Innovations

Dr. Swati Sharma is a patent agent in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm's patents and innovations practice. She has extensive experience and knowledge in gene therapy, molecular genetics, molecular biology, and disease models.

During her doctoral studies at the University of Cincinnati College of Medicine, Swati's research focused on creating gene therapy strategies for rare diseases.

Experience

During her doctoral studies at the University of Cincinnati College of Medicine, Swati's research focused on creating gene therapy strategies for rare diseases.

Education

Ph.D., Molecular Genetic, Biochemistry, and Microbiology, University of Cincinnati College of Medicine
B.Tech., Biotechnology, IMS Engineering College, Uttar Pradesh Technical University, India

Credentials

Education

Ph.D., Molecular Genetic, Biochemistry, and Microbiology, University of Cincinnati College of Medicine
B.Tech., Biotechnology, IMS Engineering College, Uttar Pradesh Technical University, India

Select Publications

Co-author with A. Hontz, C.E. Terrell, P. Arumugam, K. Risma, M. Jordan, and P. Malik, "High Level of Perforin Expression Is Required for Effective Correction of Hemophagocytic Lymphohistiocytosis," 27(10) Human Gene Therapy 847-59, 2016
Co-author with M.S. Eiymo Mwa Mpollo, E.B. Brandt, S.K. Shanmukhappa, P.I. Arumugam, A. Loberg, D. Pillis, T. Rizvi, M. Lindsey, B. Jonck, P. Carmeliet, V.K. Kalra, T.D. Le Cras, N. Ratner, M. Wills-Karp, G.K., Hershey, and P. Malik, "Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13," 126(2) The Journal of Clinical Investigation 571-84, February 2016
Co-author with M. Carmo, K.A. Risma, P. Arumugam, A.E. Hontz, C.A. Montiel-Equihua, M.E. Alonso-Ferrero, M.P. Blundell, A. Schambach, C. Baum, P. Malik, A.J. Thrasher, M.B. Jordan, and H.B. Gaspar, "Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency," 23(4) Molecular Therapy 737-45, 2015

Insights

Select Publications

Co-author with A. Hontz, C.E. Terrell, P. Arumugam, K. Risma, M. Jordan, and P. Malik, "High Level of Perforin Expression Is Required for Effective Correction of Hemophagocytic Lymphohistiocytosis," 27(10) Human Gene Therapy 847-59, 2016
Co-author with M.S. Eiymo Mwa Mpollo, E.B. Brandt, S.K. Shanmukhappa, P.I. Arumugam, A. Loberg, D. Pillis, T. Rizvi, M. Lindsey, B. Jonck, P. Carmeliet, V.K. Kalra, T.D. Le Cras, N. Ratner, M. Wills-Karp, G.K., Hershey, and P. Malik, "Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13," 126(2) The Journal of Clinical Investigation 571-84, February 2016
Co-author with M. Carmo, K.A. Risma, P. Arumugam, A.E. Hontz, C.A. Montiel-Equihua, M.E. Alonso-Ferrero, M.P. Blundell, A. Schambach, C. Baum, P. Malik, A.J. Thrasher, M.B. Jordan, and H.B. Gaspar, "Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency," 23(4) Molecular Therapy 737-45, 2015

Recent Insights

Client Highlights

On March 28, 2024, Stoke Therapeutics, a biotechnology company focused on developing RNA-based medicines to treat severe diseases, announced the pricing of its upsized underwritten public offering. The company is offering 5,555,557 shares at $13.50 per share and, in lieu of shares to investors that so choose, pre-funded warrants to purchase up to 3,703,730 shares at $13.4999. Stoke has also granted the underwriters a 30-day option to purchase up to an additional 1,388,893 shares. The gross proceeds from this offering, to be closed on or about April 2, are expected to be $125 million before expenses. Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters related to the transaction.

Learn More

Client Highlights

On January 10, 2022, Acadia Pharmaceuticals and Stoke Therapeutics announced that the companies have entered a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS), including SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest. Wilson Sonsini Goodrich & Rosati advised Stoke Therapeutics on IP matters related to the collaboration.

Learn More